Isolated spleen recurrence in a patient with lung adenocarcinoma: A case report

Yamada

et al. 2021

ATCS

Solitary splenic metastasis from primary lung cancer is extremely rare. Here, we demonstrated a solitary splenic metastasis of primary lung cancer that was difficult to distinguish from benign cystic disease. A 69-year-old-female was diagnosed as middle lobe lung cancer. Although preoperative abdominal computed tomography (CT) demonstrated a low-density splenic nodule, fluorodeoxyglucose-positron emission tomography (FDG-PET) revealed no fluorodeoxyglucose uptake in the splenic nodule. Therefore, the nodule was diagnosed as benign cystic disease and middle lobe lobectomy was performed. Postoperative pathologic examination demonstrated papillary-predominant adenocarcinoma with mucin, and the tumor was diagnosed as primary lung cancer. However, the splenic nodule continued to increase postoperatively. Splenectomy was undergone 30 months after the pulmonary resection and the splenic tumor was diagnosed as the splenic metastasis of lung cancer. In the 24 months since the splenectomy, no recurrence has been observed in the absence of treatment. Splenectomy was an effective treatment for solitary splenic metastasis of lung cancer in this case. FDG uptake in the splenic tumor was not evident due to marked mucus production.

Section: Discussioncontrasting

confidence: 64%

Solitary Splenic Metastasis of Lung Cancer Presenting as Benign Cystic Disease

Yamada

et al. 2021

ATCS

“…The gene SLC7A7, instead, is annotated to leukopenia (HP:0001882), predicted to associate with response to growth factor (GO:0070848), enriched in AD.Up, and, among others, splenomegaly (HP:0001744), associated to transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169), enriched in LC.Down. Spleen metastasis are indeed rare in LC (Iguchi et al Exp Ther Med. 2015), while growth factors-based therapies are at the forefront of AD treatment (Duncan and Valenzuela Stem Cell Res Ther.…”

Section: Resultsmentioning

confidence: 99%

Graph analytics for phenome-genome associations inference

Cirillo

Garcia-Gasulla

Cortés

et al. 2019

Preprint

Motivation: Biological ontologies, such as the Human Phenotype Ontology (HPO) and the Gene Ontology (GO), are extensively used in biomedical research to find enrichment in the annotations of specific gene sets. However, the interpretation of the encoded information would greatly benefit from methods that effectively interoperate between multiple ontologies providing molecular details of disease-related features. Results: In this work, we present a statistical framework based on graph theory to infer direct associations between HPO and GO terms that do not share co-annotated genes. The method enables to map genotypic features to phenotypic features thus providing a valid tool for bridging functional and pathological annotations. We validated the results by (a) supporting evidence of known drug-target associations (PanDrugs), protein-protein physical and functional interactions (BioGRID and STRING), and common pathways (Reactome); (b) comparing relationships inferred from early ontology releases with knowledge contained in the latest versions. Applications: We applied our method to improve the interpretation of molecular processes involved in pathological conditions, illustrating the applicability of our predictions with a number of biological examples. In particular, we applied our method to expand the list of relevant genes from standard functional enrichment analysis of high-throughput experimental results in the context of comorbidities between Alzheimer's disease, Lung Cancer and Glioblastoma. Moreover, we analyzed pathways linked to predicted phenotype-genotype associations getting insights into the molecular actors of cellular senescence in Proteus syndrome. Availability: https://github.com/dariogarcia/phenotype-genotype_graph_characterization

“…The most common histopathological subtype of lung cancer with isolated splenic metastasis was adenocarcinoma (44% of cases), followed by squamous cell cancer (17% of cases) and large-cell lung cancer (17% of cases). Surprisingly, there is no report of isolated splenic metastasis in small-cell lung cancer, although splenic metastasis in the context of multiple metastatic sites is well recognized in small-cell lung cancer [ 12 , 13 , 14 ]. One case of carcinoid with isolated spleen deposits has been reported.…”

Section: Discussionmentioning

confidence: 99%

“…In histopathology, splenic metastases appear in 3 macroscopic patterns: macronodular, micronodular, and diffuse [ 6 ]. Iguchi et al [ 14 ] mentioned that the micronodular and diffuse type might not be detectable on abdominal CT scan, although FDG-PET/CT may detect the diffuse type of splenic metastasis. In case of a macronodular pattern, the metastasis can either present as solitary or multiple nodules; the micronodular pattern can be diagnosed by the presence of scattered uniform miliary nodules, and in case of a diffuse pattern, the splenic parenchyma is completely occupied by tumor cells [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature

et al. 2017

Metastases to the spleen are rare but have been reported for different tumor entities, including breast cancer, lung cancer, colorectal cancer, ovarian cancer, and melanoma. As an isolated event, splenic metastasis from non-small-cell lung cancer (NSCLC) is exceedingly rare. Until now, only 28 cases have been reported in the medical literature. We report the case of a 66-year-old woman with NSCLC (adenocarcinoma) who presented with a synchronous, isolated splenic metastasis. Operative removal of both primary tumor and metastasis was not possible due to multiple comorbidities. Therefore, treatment was limited to combined systemic chemotherapy and simultaneous radiation of the primary tumor, which led to partial remission of the disease. Isolated metastasis to the spleen in NSCLC has been reported only 28 times in the medical literature, most often in male patients with right-sided lung tumors, most of which were adenocarcinomas. The majority of patients were asymptomatic with respect to splenic metastasis. About half of the reported cases were isolated metachronous splenic metastases. Splenectomy seems to confer a survival advantage. We review the pertinent medical literature.